Work Here?
Work Here?
Work Here?
Kelonia Therapeutics develops advanced technologies for delivering genetic material to specific tissues, aiming to treat diseases at their source. Their flagship product, KLN 1010, is an in vivo CAR T cell therapy designed for multiple myeloma, which modifies a patient's immune cells to target cancer cells directly within the body. Unlike many competitors, Kelonia emphasizes precision in treatment delivery, minimizing impact on healthy tissues. The company seeks to improve patient outcomes through partnerships and licensing agreements, with a mission focused on providing life-saving therapies and fostering a supportive culture for its employees.
Company Stage
Series A
Employees
51-200
Industries
Biotechnology, Healthcare
Total Funding
$50M
Headquarters
N/A
Founded
2021
Help us improve and share your feedback! Did you find this helpful?
Find jobs on Simplify and start your career today